JAPANESE TOP Message from the Director Information Faculty list Research Projects International Conference Entrance Exam Visitors Publication Job Vacancy International Partnerships Links Access HANDBOOK FOR INTERNATIONAL RESEARCHERS Map of Inuyama
TOPICS
BONOBO Chimpanzee "Ai" Crania photos Itani Jun'ichiro archives Guidelines for Care and Use of Nonhuman Primates(pdf) Study material catalogue/database Guideline for field research of non-human primates Primate Genome DB

Primate Research Institute, Kyoto University
Inuyama, Aichi 484-8506, JAPAN
TEL. +81-568-63-0567
(Administrative Office)
FAX. +81-568-63-0085

Copyright (c)
Primate Research Institute,
Kyoto University All rights reserved.

Contact

Japanese

Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody
Sugata K, Yasunaga J, Miura M, Akari H, Utsunomiya A, Nosaka K, Watanabe Y, Suzushima H, Koh KR, Nakagawa M, Kohara M, Matsuoka M.

Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia and inflammatory diseases. Because anti-HTLV-1 immune responses are critical for suppressing infected cells, enhancing cellular immunity is beneficial for the treatment of HTLV-1-associated diseases. Using simian T-cell leukemia virus type 1 (STLV-1) infected Japanese macaques, we analyzed the immune responses to viral antigens and the dynamics of virus-infected cells. The chemokine receptor CCR4 is expressed on STLV-1 infected cells, and administration of humanized monoclonal antibody to CCR4, mogamulizumab, dramatically decreased the number of STLV-1-infected cells in vivo. Concurrently, mogamulizumab treatment enhanced STLV-1 specific CD4(+) and CD8(+) T cell responses by simultaneously targeting CCR4(+) effector regulatory T (Treg) cells and infected cells. Mogamulizumab promoted the phagocytosis of CCR4(+) infected cells by macrophages, which likely enhanced antigen presentation. Vaccination with recombinant vaccinia virus (rVV) expressing viral antigens suppressed the proviral load and the number of Tax-expressing cells. Enhanced T-cell responses were also observed in some ATL patients who were treated with mogamulizumab. This study shows that mogamulizumab works not only by killing CCR4(+) infected cells directly, but also by enhancing T cell responses by increasing the phagocytosis of infected cells by antigen-presenting cells and suppressing CCR4(+) effector Treg cells.

   
Bibliographic information
Scientific Reports 6, 27150, 2016.
2016/06/15 Primate Research Institute